

**-Ayman A. Zayed, M.D., M.Sc., F.A.C.E., F.A.C.P.-**

School of Medicine/Jordan University Hospital

The University of Jordan

P.O.Box 13046

Amman 11942 , Jordan.

Telephone: 962797224442, 962798504465 Email: baraaayman@gmail.com

**Personal**

- Born December 28, 1964
- Married, with five children.
- Interests include chess playing, poetry, and reading.
- Nationality:    **\*Jordanian**  
                      **\*USA**

**Current Position**

Sep 2013 – Present

**Associate Professor**

Chief, Division of Endocrinology, Diabetes and Metabolism

Department of Internal Medicine

School of Medicine/Jordan University Hospital

The University of Jordan

**Amman - Jordan**

March 2008 – Sep 2013

**Assistant Professor**

Chief, Division of Endocrinology, Diabetes and Metabolism

Department of Internal Medicine

School of Medicine/Jordan University Hospital

The University of Jordan

**Amman - Jordan**

**Prior Appointments**

Oct 1998 – Oct 2000

**Chairman**

Department of Internal Medicine

Northeast Alabama Regional Medical Center

Anniston, Alabama

**U.S.A**

Oct 2000 – Oct 2002

**Representative**

Department of Internal Medicine

Northeast Alabama Regional Medical Center (NEARMC)

Anniston, Alabama

**U.S.A**

**Academic/Teaching Experience**

Sep 2013 – Present

**Associate Professor**

Chief, Division of Endocrinology, Diabetes and Metabolism

Department of Internal Medicine

School of Medicine/Jordan University Hospital  
The University of Jordan  
**Amman – Jordan**

March 2008 – Sep 2013      **Assistant Professor**  
Chief, Division of Endocrinology, Diabetes and Metabolism  
Department of Internal Medicine  
School of Medicine/Jordan University Hospital  
The University of Jordan  
**Amman, Jordan**

November 1996 – April 2006      **Clinical Assistant Professor**  
Division of Endocrinology, Diabetes, and Metabolism  
Department of Internal Medicine  
School of Medicine  
University of Alabama at Birmingham  
Birmingham, Alabama  
**U.S.A**

July 1994 – Dec 1995      **Lecturer**, Endocrinology Didactic Lectures  
Internal Medicine Residency Program  
University of Alabama at Birmingham  
Birmingham, Alabama  
**U.S.A**

Jan 1995 – June 1995      **Lecturer**, Endocrinology Teaching Course  
Internal Medicine Residency Program  
University of Alabama at Birmingham  
Baptist Medical Center  
Montgomery, Alabama  
**U.S.A**

May 1995      **Clinical Instructor**  
Correlative Endocrine Pathology Course for 1994-1995  
University of Alabama at Birmingham  
School of Medicine  
Birmingham, Alabama  
**U.S.A**

Octr 1994 – April 1995      **Preceptor**, Introduction to Clinical Medicine  
University of Alabama at Birmingham  
School of Medicine  
Birmingham, Alabama

**Other Academic Experience**

June 2013 – present      **Examiner**  
Internal Medicine Examination Committee  
Arab Medical Council  
**Amman – Jordan**



Worcester, Massachusetts

**USA**

Resident in Internal Medicine

Program Director: **Ann Errichetti, M.D.**

July 1985 – July 1989

Jordan University Program in Internal Medicine

University Hospital

**Amman, Jordan**

Intern and Resident in Internal Medicine

Program Director: **Abdallah Abbadi, M.D.**

### **Certification and Recertification**

1995 (No. 149098) Diplomat, American Board of Endocrinology, Diabetes and Metabolism (1<sup>st</sup> attempt)

2005 Recertified, Diplomat American Board of Internal Medicine (1<sup>st</sup> attempt)

1993 (No. 149098) Diplomat, American Board of Internal Medicine (1<sup>st</sup> attempt)

1989 Master's Degree in Medical Sciences "M.Sc." (1<sup>st</sup> attempt)

1985 Bachelor of Medicine and Surgery "M.D." (1<sup>st</sup> attempt)

1979 National Jordanian Education Matriculate (1<sup>st</sup> attempt)

### **Awards/Honors**

1993 Resident Teacher of the Year Award  
Medical Center of Central Massachusetts  
Worcester, Massachusetts  
**USA**

1993 In-training Examination in Internal Medicine, 100<sup>th</sup> Percentile  
**USA**

1979 National Education Matriculate Examination  
(97.3%) Ranked 7<sup>th</sup> of all Jordanians  
**Jordan**

### **Work Experience**

March 2008 – Present **Chief and Consultant in Endocrinology, Diabetes and Metabolism**  
School of Medicine/Jordan University Hospital  
The University of Jordan  
Amman – Jordan

April 2006 – March 2008 **Consultant Endocrinologist.**  
King Fahd Armed Forces Hospital  
Jeddah, Saudi Arabia

Feb1996 – April 2006 **Internist/Endocrinologist, Anniston Medical Clinic**  
**Staff Physician, Department of Internal Medicine/Endocrinology**  
Northeast Alabama Regional Medical Center, and String fellow  
Memorial Hospital

Anniston, Alabama  
**USA**

Nov 1989 – April 1991 Senior Medical Resident, Security Forces Hospital. **Riyadh, Saudi Arabia**

July 1986 – Nov 1989 Medical Resident, Jordan University Hospital. **Amman, Jordan**

### **Memberships and Fellowships**

July 2013- Present Jordan Chapter- **AACE**  
 2000- Present Fellow, American College of Endocrinology – **F.A.C.E.**  
 Nov1997- Present Fellow, American College of Physicians/American Society of Internal  
 Medicine – **F.A.C.P.**  
 1994- Present American Association of Clinical Endocrinologists (**AACE**)  
 1986- Present Jordanian Medical Association

### **Institutional and Committee Memberships**

Jan 2015-present **Credential Committee**  
 Jordan University Hospital  
 Amman, Jordan

Jan 2015-present **Institutional Review Board (IRB)**  
 Jordan University Hospital  
 Amman, Jordan

Sept 2014-present **Scientific Research Council Committee**  
 Jordan University Hospital  
 Amman, Jordan

June 2013-Present **Internal Medicine Examination Committee**  
 Arab Medical Council  
 Amman, Jordan

Feb2013-Present **Endocrinology and Diabetes Scientific and Examination  
 Committee**  
 Jordanian Medical Council.  
**Amman, Jordan**

Aug2012- Present **Medical Record Committee**  
 Jordan University Hospital.  
**Amman, Jordan**

Jan2010- Present **Endocrinology and Diabetes Committee**  
 Representative of The University of Jordan  
 Jordanian FDA  
**Amman, Jordan**

- Jan2010- Present                    **Endocrinology and Diabetes Tenders Committee**  
Jordan University Hospital  
**Amman, Jordan**
- Jan2009- Present                    **Endocrinology and Diabetes Committee**  
Representative of The University of Jordan  
Joint Procurement Department  
**Amman, Jordan**
- 2009                                    **Medical Students Clinical Training Committee**  
School of Medicine  
The University of Jordan  
**Amman, Jordan**
- 2008                                    **Former Medical Graduates Committee**  
School of Medicine  
The University of Jordan  
**Amman, Jordan**
- Oct 1998 – Sep 2002                **Executive Committee**  
Northeast Alabama Regional Medical Center  
Anniston, Alabama  
**USA**
- Feb 1996 – Feb 2002                **Education Committee**  
String fellow Memorial Hospital  
Anniston, Alabama  
**USA**
- Community Activities**
- 2010                                    Public Health Campaign  
Medical Students/ School of Medicine  
The University of Jordan  
**Amman, Jordan**
- 1997 – 2006                            Educational Lectures in Diabetes Mellitus (for Diabetic patients)  
Anniston, Alabama  
**USA**
- 1997 – 2006                            Education Lectures in Diabetes Mellitus (for Diabetic patients)  
Heflin, Alabama  
**USA**
- 1994                                    Instructor, Camp Seale Harris – Camp for Diabetic Children  
Alexandria City, Alabama  
**USA**

**Presentations**

March 2015

**Poster Presentation**

The Emerging role of Serum IGF-I/IGFBP-3 ratio in the Diagnosis of Children with Growth Hormone Deficiency .

**Ayman A. Zayed** , et al.

ENDO 2015 - The Endocrine Society's 97th Annual Meeting & Expo  
Convention Center -San Diego, CA, March 6th, 2015

**USA**

June 2014

**Poster Presentation**

Is Hashimoto's Thyroiditis a Risk Factor for Medullary Thyroid Carcinoma ? Our Experience and a Literature Review.

**Ayman A. Zayed**, Moaath K. Mustafa Ali, Omar M. Jaber, et al.

The Endocrine Society's 97<sup>th</sup> Annual Meeting and Expo.  
Chicago, Il

**USA**

Jun2013

**Poster Presentation**

Predetermined Anti-diabetic drug regimen adjustments during Ramadan fasting: Evaluation of safety.

**Ayman A.Zayed**, Awni Shahait, Hamzah Zeidan, Munther Momani and Al-Motassem Yousef.

The Endocrine Society's 96<sup>th</sup> Annual Meeting and Expo.  
San Francisco, CA

**USA**

Jun 2013

**Poster Presentation**

Multiple Osteolytic lesions, Café-au-lait spots, axillary freckling with Pseudoacromegaly: A new syndrome?

Munther Momani, M. H. Ramzown and **Ayman A. Zayed**

The Endocrine Society's 96<sup>th</sup> Annual Meeting and Expo.  
San Francisco, CA

**USA**

2009

**Invited Faculty**

Internal Medicine Board Review Course  
King Hussain Cancer Centre (KHCC)

**Amman, Jordan**

2008

**Invited Faculty**

Internal Medicine Board Review Course  
King Hussain Cancer Centre (KHCC)

**Amman, Jordan**

April 2007

**Invited Faculty**

King Faisal Specialist Hospital Internal Medicine Board Review course  
for Arab and Saudi Board.  
**Jeddah, Saudi Arabia**

April 2006

**Invited Faculty**  
King Faisal Specialist Hospital Internal Medicine Board Review course  
for Arab and Saudi Board.  
**Jeddah, Saudi Arabia**

Oct 1997

**Invited Speaker**  
“Glucocorticoid remediable Aldosteronism” Endocrine Grand Rounds  
Emory University.  
Atlanta, Georgia  
**USA**

**Conferences**

(Too Many to Count).

**Special Skills in Endocrinology**

- Fine Needle Thyroid Biopsy
- Thyroid Ultrasound
- Licensed to Perform Radioactive Iodine Therapy
- Bone Densitometry

**Licensure**

1993

**State of Alabama (18652)**

1986

**Jordan**

**Research Affiliations**

9/1999 – April 2006

**Clinical Investigator**  
Pinnacle Research Group, LLC  
Anniston, Alabama  
**USA**

**Book Chapters and Publications**

**Zayed A.A.**, Stock J.L., Liepman M., Wollin M., Longcope C. “Feminization as a Result of Both Peripheral Conversion of Androgens and Direct Estrogen Production from an Adrenocortical Carcinoma.” *J Endo Inv.* 17:275-278. 1994

**Zayed A.A.**, Frank S.J., Diabetes and Metabolism. In Cooper J.A., Pappas P.G. (eds): *Cecil Review of General Internal Medicine*. 6<sup>th</sup> Edition, Philadelphia. W.B. Saunders Company. 1996 (book chapter)

Hayne V., **Zayed A.A.**, Endocrine/Reproductive and Calcium and Bone Diseases. In Cooper J.A., Pappas P.G. (eds): *Cecil Review of General Internal Medicine*. 6<sup>th</sup> Edition, Philadelphia. W.B. Saunders Company. 1996 (book chapter)

Pittman C.S., **Zayed A.A.**, Myxedema Coma. In Bardin CW (ed): *Current Therapy in Endocrinology and Metabolism*. 6<sup>th</sup> Edition. St. Louis, Mosby Year Book, Inc. 1997 (book chapter)

Al-Amer R.M, Sobeh M.M., **Zayed A.A.**, Al-domi H.A. “Depression among adults with Diabetes in Jordan: Risk factors and relationship to blood sugar control” *Journal of Diabetes and its Complications* 25:247-252,2011.

**Zayed A.A.**, Shahait A.D., Ayoub M.N., Yousef A. “Smokers’ hair: Does smoking cause premature hair graying?” *Indian Dermatology Online Journal* 4:90-92 , 2013 .

**Zayed A.A.**, Alzubaidi M, Atallah S, Momani M, Al-Delaimy W, “ Should Food Intake and Circadian Rhythm be Considered When Measuring Serum Calcitonin Level ? “ *Endocrine Practice* 19(No.4):620 – 629,2013 .

**Zayed A. A.**, Shahait A. D., Zeidan H., Momani M., Yousef A., “Predetermined Anti-diabetic drug regimen adjustments during Ramadan fasting: Evaluation of safety.” [ Abstract], *Endocr rev, Vol.34 (03\_Meeting Abstracts)*: SUN-830

Momani M., Ramzown M. H., **Zayed A. A.**, “Multiple Osteolytic lesions, Café-au-lait spots, axillary freckling with Pseudoacromegaly: A new syndrome?” [ Abstract], *Endocr rev, Vol.34 (03\_Meeting Abstracts)*: MON-307.

**Zayed A. A.**, Mustafa Ali M., Momani M., “The Prevalence of Growth Hormone Deficiency among Children of Short Stature in Jordan and its Relation to Consanguinity.” [ Abstract], *Endocr rev, Vol.34 (03\_Meeting Abstracts)*: SUN-641

Al-Tae M. A., **Zayed A. A.**, Abood S. N., Al-Ani M. A., Al-tae A. M., Hassani H. A., “Mobile-Based Interpreter of Arterial Blood Gases Using Knowledge-Based Expert System” *International Journal of Pervasive Computing and Communications Vol. 9 No.3: 270 – 288,2013 .*

**Zayed A.A.**, Mustafa MK, Al-Ani MA, et al. “The Prevalence of Isolated Growth Hormone Deficiency among Children of Short Stature in Jordan and its Relationship with Consanguinity” *Clinical Endocrinology (2014)*

**Zayed A.A.**, Mustafa MK, Jaber OM, et al. “Is Hashimoto’s Thyroiditis a Risk Factor for Medullary Thyroid Carcinoma ? Our Experience and a Literature Review.” *Endocrine (2014)*

**Zayed A.A.**, et al. “The Emerging role of Serum IGF-I/IGFBP-3 ratio in the Diagnosis of Children with Growth Hormone Deficiency.” Submitted .

Momani, Munther S., **Ayman A. Zayed**, & Faris G. Bakri. "Subacute thyroiditis following influenza vaccine: a case report and literature review." *Italian Journal of Medicine*[Online], 9.3 (2015): n. pag. Web. 23 Jul. 2015.

Y.G. Al hasan;M.A. Zmaili; V.Dabravolskaite; **A.A. Zayed**, “Diabetes Mellitus and Cardiovascular Disease”, in Complex Cardiac, Management of Multi Organ System Dysfunction, ed. by Omar M. Lattouf, et al. e-book,2016.

## **Research**

### **Co-Investigator (site)** - SmithKline Beecham Protocol 265805/014. (1999)

P.R.O.T.E.C.T. Study. Precose: Resolution of Optimal Titration to Enhance Current Therapies. A Double-Blind, Multicentre, Parallel Group Study to Compare the Efficacy and Safety of oral SB-265805 320mg Once Daily Versus oral Levofloxacin 250mg Once Daily for 10 Days in the Treatment of Pyleonephritis or Complicated Urinary Tract Infections (UTI).

### **Principal-Investigator (site)** - Glaxo Wellcome Protocol PPA30003. (1999)

A Multicenter, Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled, Clinical Evaluation of {Oral GI262570} Sodium Tablets (2.5, 5.0, and 7.5 mg) in Combination with Current Insulin Therapy for 26 Weeks Duration in Subjects with Type 2 Diabetes Mellitus Who are Inadequately Controlled with Insulin Alone.

### **Principal-Investigator (site)** - R.W. Johnson Protocol TOPMAT-NP-003. (2000)

A Double-Blind, Placebo-Controlled, Parallel Group, Dose Response Study to Evaluate the Efficacy and Safety of {Topiramate} Versus Placebo in the Relief of Pain in Diabetic Peripheral Neuropathy.

### **Principal-Investigator (site)** -Glaxo-Wellcome Protocol PPA 30015. (2000)

A Multi-center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Pilot Study of 3 Months Treatment of Oral {GI262570} 7.5 mg Once Daily, Pioglitazone 45 mg Once Daily, and Rosiglitazone 4 mg Twice Daily on Postprandial Glucose following a SUSTACAL™ Meal Challenge in Subjects with Type 2 Diabetes Mellitus.

### **Co-Investigator (site)** - SmithKline Beecham Protocol BRL 49653/048. (2000-2005)

A Randomized, Double-blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of {Rosiglitazone} Monotherapy Compared to {Metformin} or {Glyburide/glibenclamide} in Patients with Drug-Naïve, Recently Diagnosed Type 2 Diabetes Mellitus ( $\leq 2$  years).

### **Co-Investigator (site)** - Glaxo Wellcome Protocol PPA30016. (2000)

A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study to Assess the Efficacy and Safety of {GI262570 Sodium Tablets} (2.5 mg, 5 mg, and 7.5 mg) Administered as a Daily Dose for 8 Weeks in Patients with Dyslipidemia.

### **Co Investigator (site)** - Novartis Protocol COX 189A-114. (2000)

A 13-week multi-center randomized double-blind double-dummy placebo-controlled parallel group trial of 2 doses of {COX189 (200 and 400 mg ad)} in patients with rheumatoid arthritis using {celecoxib (200 mg bid)} as a comparator.

### **Co- Investigator (site)** - Protocol CV138-055. Bristol-Myers Squibb. 2000-2001

A Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of {Rosiglitazone} Added on to a Background of {Metformin/Glyburide} Tablets in Subjects with Type 2 Diabetes Mellitus Who have Inadequate Glycemic Control on {Metformin/Glyburide} Therapy.

### **Principal Investigator (site)** - Bristol-Myers Squibb Protocol CV138-058. (2000)

A Multi-center, Randomized, Double-Blind, Active Control Trial to Compare the Safety and Efficacy of A New Formulation of {Metformin/Glyburide} Tablets (500/1.25mg) to Metformin Monotherapy as First Line Therapy in Patients with Type 2 Diabetes Mellitus who have Inadequate Glycemic Control with Diet and Exercise.

Principal Investigator (site) - Bristol-Myers Squibb Protocol CV137-120. (2000)  
Omapatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE).

Co Investigator (site) - Novartis Protocols CHTF919/2201 & 2202. (2001)  
A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Multi-center Study to Assess the Efficacy, Safety and Tolerability of {tegaserod} Given Orally at Three Dose Levels (4mg, 12 mg, or 24mg) and Placebo in Patients with Functional Dyspepsia (FD) and Documented Normal/Delayed Gastric Emptying.

Principal Investigator (site) - Bristol-Myers Squibb Protocol CV138-061. (2001)  
A Multicenter, Randomized, Double-Blind, Clinical Trial Comparing The Safety And Efficacy Of Metformin/Glyburide tablets to Metformin Plus Rosiglitazone Therapy In Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With {Metformin} Monotherapy.

Co-Investigator (site) - Novartis Protocol CFOR258-F2302. (2001)  
A 12-week randomized, multi-center, double-blind, double-dummy, placebo and active controlled, parallel group study evaluating the safety and efficacy of Formoterol fumarate (10 µg b.i.d.) delivered by the multi-dose dry powder inhaler (MDDPI) versus placebo versus albuterol pMDI q.i.d. in patients with persistent asthma.

Principal Investigator (site) - Eli Lilly Protocol H6E-US-GLAI. (2001)  
Pioglitazone versus Rosiglitazone in Subjects with Type 2 Diabetes Mellitus and Dyslipidemia.  
A Multicenter, Stratified, Randomized, Double-Blind, Parallel-Group, Step-Up Comparison

Co-Investigator (site) - Glaxo-Wellcome Protocol SAS40027. (2001)  
A Randomized, Double-Blind, Parallel Group, Comparative Trial of {Salmeterol/Fluticasone Propionate} Combination Product {50/100mcg DISKUS Inhaler BID} versus {Fluticasone Propionate 250mcg DISKUS Inhaler BID} in Adolescents and Adults with Moderate Persistent Asthma.

Principal Investigator (site) - Astra Zeneca Protocol ZD4522IL/0065. (2001)  
A 6-week, Open-Label, Dose-comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin versus Atorvastatin, Cerivastatin, Pravastatin and Simvastatin in subjects With Hypercholesterolemia.

Principal Investigator (site) - Bristol-Myers Squibb Protocol CV138-060. (2001)  
A Double-Blind Randomized Study to Evaluate the Effects of Fixed Metformin/Glipizide therapy in subjects with Type 2 Diabetes Mellitus who have inadequate glycemic control on half-maximum to maximum of the labeled doses of Sulfonylurea monotherapy.

Co Investigator (site) - Novartis Protocol CCOX189-109. (2001)  
A 13 week, international, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial assessing the safety and efficacy of 2 doses {COX189 (200 mg and 400 mg od)} in patients with knee primary osteoarthritis, using Celecoxib (200 mg od) as a comparator.

Principal Investigator (site) - Schwarz Protocol SP614. (2001)

A Randomized, Double-Blind Placebo Controlled Trial to Investigate Safety and Efficacy of {SPM 927} in Painful Diabetic Neuropathy.

Principal Investigator (site) - Restoragen Protocols BN02-C006 and C007. (2001)

A Study Comparing Safety and Efficacy of Three Doses of Recombinant Glucagon-like Peptide 1 (rGLP-1) (1.25 pmol/kg/min, 2.5 pmol/kg/min, and 5.0 pmol/kg/min) to Placebo Given by Continuous Subcutaneous Infusion in Combination with Metformin and Sulfonylurea Over 12 Weeks in Patients with Type 2 Diabetes Mellitus.

Principal Investigator (site) - Novartis Protocol CTRI476G2303. (2001)

Multicenter, double-blind, randomized, placebo-control, parallel-group study to evaluate the safety and efficacy of three dose groups {Trileptal®} in patients with neuropathic pain due to diabetic neuropathy.

Principal Investigator (site) - Bristol-Myers Squibb Protocol CV168-006. (2001)

A Randomized, Double-Blind, Dose Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of {BMS-298585} in Patients With Type 2 Diabetes.

Co- Investigator (site) - Solvay Protocol S2413006. (2002)

A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Investigate the Safety and Efficacy of 2 mg TID of Cilansetron Over 12 Weeks in Diarrhea-Predominant Irritable Bowel Syndrome Subjects.

Sub Investigator (site) - Novartis Protocol CHTF919-2209. (2002)

A one-year open-label surveillance study to assess the long-term safety and tolerability of tegaserod (2 mg b.i.d. and/or 6 mg b.i.d.) in patients with symptoms of functional dyspepsia.

Principal Investigator (site) - Astra Zeneca Protocol ZD4522IL/0068. (2002)

An Open-label, Randomized, Multi-center, Phase IIIb, Parallel Group Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with {Rosuvastatin} in High Risk Subjects with Type IIa and IIb Hypercholesterolemia.

Principal Investigator (site) - Amylin Protocol AC2993-112. (2002)

A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects with Type 2 Diabetes Mellitus Treated With Metformin Alone.

Principal Investigator (site) - Amylin Protocol AC2993-113. (2002)

A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects with Type 2 Diabetes Mellitus Treated With a Sulfonylurea Alone.

Principal Investigator (site) - Amylin Protocol AC2993-115. (2002)

A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects with Type 2 Diabetes Mellitus Treated With Metformin and a Sulfonylurea.

Sub Investigator (site) - BioCryst Protocol BC-01-03. (2002)

A Multicenter, Randomized, Double-Blinded Placebo-Controlled Study to Assess The Efficacy And Safety Of {RWJ-270201} In The Treatment Of Acute Influenza A And B Infections In Healthy Adults.

Principal Investigator (site) - Astra Zenenca Protocol ZD4522IL/0091. (2002)

A 48-Week Open-Label, Non-Comparative, Multicenter, Phase IIIb Study To Evaluate The Efficacy and Safety of the Lipid-Regulating Agent {Rosuvastatin} in the Treatment of Subjects with Fredrickson Type IIa and Type IIb Dyslipidemia, Including Heterozygous Familial Hypercholesterolemia.

Sub Investigator(site) - Sepracor Protocol SC091-050. (2002)

A Double-Blind, Double-Dummy, Randomized, Placebo- and Active -Controlled, Multicenter, Parallel-Group Study of {(R, R)-Formoterol} in the Treatment of Subjects with Chronic Obstructive Pulmonary Disease.

Co- Investigator (site) - Pfizer Protocol A3191051. (2002)

Study of the efficacy and tolerability of once daily {Celebrex®} and twice daily {naproxen} vs. placebo in the treatment of African American subjects with osteoarthritis of the knee.

Co- Investigator (site) - Novartis Protocol COX109-117 and Protocol COX109-2332. (2002)

An international, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, 52-week gastrointestinal clinical safety study to demonstrate that {COX189} (400 mg od) reduces the risk to develop complicated ulcers as compared to {NSAIDS (naproxen 500 mg bid and ibuprofen 800 mg tid)}, in osteoarthritis patients.

Co-Investigator (site) -Pfizer Protocol A3191052. (2002)

Study of the efficacy and tolerability of once daily {Celebrex®} and twice daily {naproxen} vs. placebo in the treatment of Asian American subjects with osteoarthritis of the knee.

Co-Investigator (site) - GlaxoSmithKline Protocol SMS40330. (2002)

A Randomized, Multi-Center, Cross-Over Comparison of Salmeterol Xinafoate Inhalation Powder (50mcg BID) via the DISKUS and Salmeterol Xinafoate Inhalation Aerosol (42mcg BID) via the Metered Dose Inhaler on Measures of Device Preference in Subjects with COPD.

Principal Investigator (site) - Bristol-Myers Squibb Protocol CV168018. (2003)

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of {BMS-298585} as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control.

Principal Investigator (site) - Bristol-Myers Squibb Protocol CV168022. (2003)

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of {BMS-298585} as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone.

Principal Investigator (site) -Protocol 01-02-TL-559-013 (2003)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of a Combination of {TAK-559} and Glyburide Compared to Placebo and Glyburide in the Treatment of Patients with Type 2 Diabetes Mellitus.

Principal Investigator (site) - Protocol 014-00. (2003)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose-Range Finding Study of Once-Daily Dosing of L-000224715 in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control.

Principal Investigator (site) - Protocol B3A20005. (2004)

A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of GW427353B at 10 mg, 25 mg, 50 mg and 100 mg, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus.

Co-Investigator v - Protocol 712753/007/004 (2004)

A randomized, double-blind trial to evaluate the efficacy and safety of fixed dose Rosiglitazone Metformin combination therapy compared to both Rosiglitazone and Metformin Monotherapy in drug naïve type 2 diabetes mellitus subjects.

Principal Investigator (site) -Protocol SP742 (2004)

A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of {200, 400, and 600 mg/day of SPM 927} in Subjects with Painful Distal Diabetic Neuropathy

Principal Investigator (site) - Protocol IPT-2004-001 (2004)

An Open-Label, Randomized, 2-Way Crossover Study To Assess The Bioequivalence, Pharmacokinetics, Pharmacodynamics, And Safety Of Single And Repeat Doses Of {Somatrem} Compared With Protropin®

Principal Investigator (site) -Protocol SYR-322-002 (2004)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study to Determine the Safety, Pharmacokinetic and Pharmacodynamic Effects and Efficacy of {SYR110322} in Patients with Type 2 Diabetes Who are Either Newly Diagnosed or Managed with Diet and Exercise Alone for the Past 3 Months

Principal Investigator (site) Protocol 01-02-TL-559-013 (2004)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of a Combination of { } and lyburide Compared to Placebo and Glyburide in the Treatment of Patients with Type 2 Diabetes Mellitus.

Principal Investigator (site) Protocol 01-02-TL-559-014 (2004)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of { } in the Treatment of Patients with Type 2 Diabetes Mellitus.

Principal Investigator (site) Protocol SB275833/030 (2004)

Studies 030A and 030B: Two Identical Double-blind, Double-dummy, Multicenter, Comparative Phase III Studies of the Safety and Efficacy of Topical 1% SB-275833, Applied Twice Daily, versus Oral Cephalexin, 500 mg in Adults, or 12.5 mg/kg (250 mg/5 ml) in Children, Twice Daily, in the Treatment of Uncomplicated Secondarily Infected Traumatic Lesions

Principal Investigator (site) Protocol # SK&F-105517/902 (2005)

A Randomized, Double-Blind, Placebo-Controlled, PK/PD Modeling, Multicenter Study to Compare the  $\beta$ 1-Blocking Effects of Carvedilol Phosphate MR Capsule Formulation to COREG® Immediate

Release Tablets at steady State in Adult Patients with Essential Hypertension, by Evaluating Heart Rate Response to Bicycle Ergometry.

Principal Investigator (site) Protocol # SB-462795/002 (2005)

A Randomized, Single-Blind, Placebo-Controlled, Dose-Rising Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamics of Single and Repeat Oral Doses of SB-462795 in Healthy Postmenopausal Women.

Principal Investigator (site) Protocol SYR-322-003 (2005)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Comparison Study to Determine the Efficacy and Safety of SYR110322 in Patients with Type 2 Diabetes, Who are Either Receiving No Current Treatment or Currently Treated with Diet and Exercise, a Sulfonylurea, Metformin, or a Combination of a Sulfonylurea and Metformin.

Sub-Investigator (site) Protocol CCOX189A2428 (2005)

A 4-week, multicenter, randomized, double-blind, double-dummy, parallel-group ambulatory blood pressure monitoring study to demonstrate that treatment with lumiacoxib 100 mg o.d. results in 24-hour blood pressure profile superior to ibuprofen 600 mg t.i.d. in OA patients with controlled hypertension.

Sub-Investigator (site) (Protocol 712753/007 & 00 (2005)

A randomized, double-blind trial to evaluate the efficacy and safety of fixed dose { } combination therapy compared to both rosiglitazone and metformin monotherapies in drug naïve type 2 diabetes mellitus subjects.

### **Master Theses Supervision**

Sep 2010-june 2011

“Impact Of Clinical Pharmacist Intervention On Health Outcomes In Patients With Diabetes Mellitus”

By Mohammad khalaf dweib  
Supervisors: Bulatova N.AbuRuz S. , **Zayed A.A.**  
**School of pharmacy, The University of Jordan.**

March 2013-Present

“The Association Between Apolipoprotein E Polymorphism And Response To Statins In Jordanian Hyperlipidemic Patients.”

By Rasha M. Mustafa  
Supervisors : Gharayba M. , **Zayed AA**  
**School of medicine, The University of Jordan.**